FC gamma receptor polymorphisms in patients with immune thrombocytopenia

References

• McKenzie CG, Guo L, Freedman J, et al. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol. 2013;163(1):10–23. doi: 10.1111/bjh.12480
   PubMed Web of Science ®Google Scholar
• McMillan R. Chronic idiopathic thrombocytopenic purpura. N Eng J Med. 1981;304(19):1135–1147. doi: 10.1056/NEJM198105073041904
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Eng J Med. 2002;346(13):995–1008. doi: 10.1056/NEJMra010501
   PubMed Web of Science ®Google Scholar
• Lev PR, Grodzielski M, Goette NP, et al. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. Br J Haematol. 2014;165(6):854–864. doi: 10.1111/bjh.12832
   PubMed Web of Science ®Google Scholar
• Woods VLJr, Oh EH, Mason D, et al. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood. 1984;63(2):368–375.
   PubMed Web of Science ®Google Scholar
• He R, Reid DM, Jones CE, et al. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994;83(4):1024–1032.
   PubMed Web of Science ®Google Scholar
• Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88(2):167–174. doi: 10.1111/j.1600-0609.2011.01718.x
   PubMed Web of Science ®Google Scholar
• Zhao C, Li X, Zhang F, et al. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica. 2008;93(9):1428–1430. doi: 10.3324/haematol.12889.
   PubMed Web of Science ®Google Scholar
• Leytin V, Mykhaylov S, Starkey AF, et al. Intravenous immunoglobulin inhibits anti-IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol. 2006;133(1):78–82.
   PubMed Web of Science ®Google Scholar
• Winkler J, Kroiss S, Rand M, et al. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol. 2012;156(4):508–515. doi: 10.1111/j.1365-2141.2011.08973.x
   PubMed Web of Science ®Google Scholar
• Satoh T, Pandey JP, Okazaki Y, et al. Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;124(6):796–801. doi: 10.1111/j.1365-2141.2004.04843.x
   PubMed Web of Science ®Google Scholar
• Foster CB, Zhu S, Erichsen HC, et al. Polymorphisms in inflammatory cytokines and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol. 2001;113(3):596–599. doi: 10.1046/j.1365-2141.2001.02807.x
   PubMed Web of Science ®Google Scholar
• Rocha AM, DeSouza C, Rocha GA, et al. Research paper: IL1RN VNTR and IL2−330 polymorphic genes are independently associated with chronic immune thrombocytopenia. Br J Haematolol. 2010;150(6):679–684. doi: 10.1111/j.1365-2141.2010.08318.x
   PubMed Web of Science ®Google Scholar
• Zhao H, Du W, Gu D, et al. DNMT3B 579g>T promoter polymorphism and the risk for idiopathic thrombocytopenic purpura in a Chinese population. Acta Haematol. 2009;122(1):31–35. doi: 10.1159/000235616
   PubMed Web of Science ®Google Scholar
• Breunis WB, van Mirre E, Bruin M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood. 2007;111(3):1029–1038. doi: 10.1182/blood-2007-03-079913
   PubMed Web of Science ®Google Scholar
• Pavkovic M, Georgievski B, Cevreska L, et al. CTLA-4 Exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol. 2003;72(2):147–149. doi: 10.1002/ajh.10278
   PubMed Web of Science ®Google Scholar
• Li H, Ge J, Zhao H, et al. Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population. Platelets. 2011;22(1):37–42. doi: 10.3109/09537104.2010.521601
   Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Pandey JP, et al. HLA class II alleles in Japanese patients with immune thrombocytopenic purpura. Associations with anti-platelet glycoprotein autoantibodies and responses to splenectomy. Tissue Antigens. 2000;56(4):337–343. doi: 10.1034/j.1399-0039.2000.560405.x
   PubMedGoogle Scholar
• Van der Pol W, van de Winkel JGJ. Igg receptor polymorphisms: risk factors for disease. Immunogenetics. 1998;48(3):222–232. doi: 10.1007/s002510050426
   PubMed Web of Science ®Google Scholar
• Van de Winkel JGJ, Capel PJA. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993;14(5):215–221. doi: 10.1016/0167-5699(93)90166-I
   PubMedGoogle Scholar
• Salmon JE, Edberg JC, Brogle NL, et al. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest. 1992;89(4):1274–1281. doi: 10.1172/JCI115712
   PubMed Web of Science ®Google Scholar
• De Haas M, Koene HR, Kleijer M, et al. A triallelic Fcγ receptor IIIA polymorphism influences the binding of human IgG by NK cell Fcγ receptor IIIA. J Immunol. 1996;156(8):2948–2955.
   PubMed Web of Science ®Google Scholar
• Tamm A, Schmidt RE. The binding epitopes of human CD 16 (Fcγ RIII) monoclonal antibodies: implication for ligand binding. J Immunol. 1996;157(4):1576–1581.
   PubMed Web of Science ®Google Scholar
• Karassa FB, Trikalinos TA, Ioannidis JP. FcgammaRIIa-SLE Meta-Analysis Investigators. Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 2002;46(6):1563–1571. doi: 10.1002/art.10306
   PubMed Web of Science ®Google Scholar
• Manager K, Repp R, Jansen M, et al. Fcgamma receptor IIa, IIIa and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis. 2002;61(9):786–792. doi: 10.1136/ard.61.9.786
   PubMed Web of Science ®Google Scholar
• Vedeler CA, Myhr KM, Nyland H. Fc receptors for immunoglobulin G – a role in the pathogenesis of guillain–barré syndrome and multiple sclerosis. J Neuroimmunol. 2001;118(2):187–193. doi: 10.1016/S0165-5728(01)00344-7
   PubMed Web of Science ®Google Scholar
• Wolff AS, Myhr KM, Vedeler CA, et al. Fcγ receptor polymorphisms are not associated with autoimmune Addison's disease. Scand J Immunol. 2007;65(6):555–558. doi: 10.1111/j.1365-3083.2007.01932.x
   PubMed Web of Science ®Google Scholar
• Brandt JT, Isenhart C, Osborne JM, et al. On the role of platelet FcγRIIA phenotype in heparin induced thrombocytopenia. Thromb Haemost. 1995;74(6):1564–1572.
   PubMed Web of Science ®Google Scholar
• Arepally G, McKenzie SE, Jiang XM, et al. FcγRIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin induced thrombocytopenia and thrombosis. Blood. 1997;89(2):370–375.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi: 10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest. 1998;102(12):2146–2155. doi: 10.1172/JCI5084
   PubMed Web of Science ®Google Scholar
• Carcao MD, Blanchette VS, Wakefield CD, et al. Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol. 2003;120(1):135–141. doi: 10.1046/j.1365-2141.2003.04033.x
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low affinity Fcγ receptor polymorphisms in control and disease populations. Blood. 2000;94(7):4220–4232.
   Google Scholar
• Grecco M, Santos VC, Pereira KM, et al. Fc gamma receptor IIIa polymorphism is not associated with susceptibility to systemic lupus erythematosus in Brazilian patients. Rev Brazil Reumatol. 2016;56(6):515–520. doi: 10.1016/j.rbr.2016.06.004
   PubMed Web of Science ®Google Scholar
• Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100(5):1059–1070. doi: 10.1172/JCI119616
   PubMed Web of Science ®Google Scholar
• Liu D, Tian Y, Sun D, et al. The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-hodgkin lymphoma: a meta-analysis. Ann Hematol. 2016;95(9):1483–1490. doi: 10.1007/s00277-016-2723-x
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Yavuz D, Zimmermann M, et al. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Ann Hematol. 2016;95(9):1503–1512. doi: 10.1007/s00277-016-2731-x
   PubMed Web of Science ®Google Scholar
• Fujimoto TT, Inoue M, Shimomura T, et al. Involvement of Fcγ receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol. 2001;115(1):125–130. doi: 10.1046/j.1365-2141.2001.03109.x
   PubMed Web of Science ®Google Scholar
• Williams Y, Lynch S, McCann S, et al. Correlation of platelet FcγRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura. Br J Haematol. 1998;101(4):779–782. doi: 10.1046/j.1365-2141.1998.00802.x
   PubMed Web of Science ®Google Scholar
• Kyogoku C, Dijstelbloem HM, Tsuchiya N, et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 2002;46(5):1242–1254. doi: 10.1002/art.10257
   PubMed Web of Science ®Google Scholar